In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were Orthoplex White Liposomal Glutathione 50g Liposomal Glutathione Net Pharmacy